[go: up one dir, main page]

WO2014169845A3 - 4,5-dihydro-pyrazolo [3, 4-c] pyrid-2-ones, preparation method and application thereof - Google Patents

4,5-dihydro-pyrazolo [3, 4-c] pyrid-2-ones, preparation method and application thereof Download PDF

Info

Publication number
WO2014169845A3
WO2014169845A3 PCT/CN2014/075683 CN2014075683W WO2014169845A3 WO 2014169845 A3 WO2014169845 A3 WO 2014169845A3 CN 2014075683 W CN2014075683 W CN 2014075683W WO 2014169845 A3 WO2014169845 A3 WO 2014169845A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrid
pyrazolo
dihydro
ones
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2014/075683
Other languages
French (fr)
Chinese (zh)
Other versions
WO2014169845A2 (en
Inventor
魏用刚
邱关鹏
卢泳华
余彦
雷柏林
王松
黄清平
高秋
楚洪柱
祝国智
罗新峰
倪丽军
陈娅姝
邓炳初
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Haisco Pharmaceutical Co Ltd
Original Assignee
Sichuan Haisco Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Haisco Pharmaceutical Co Ltd filed Critical Sichuan Haisco Pharmaceutical Co Ltd
Priority to CN201480003262.1A priority Critical patent/CN105026392B/en
Publication of WO2014169845A2 publication Critical patent/WO2014169845A2/en
Publication of WO2014169845A3 publication Critical patent/WO2014169845A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to 4,5-dihydro-pyrazolo [3, 4-c] pyrid-2-ones, as shown in Formula (I), and to a preparation method and an application thereof; the definition of each substituent in the Formula (I) compound is the same as the definition found in the description.
PCT/CN2014/075683 2013-04-19 2014-04-18 4,5-dihydro-pyrazolo [3, 4-c] pyrid-2-ones, preparation method and application thereof Ceased WO2014169845A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201480003262.1A CN105026392B (en) 2013-04-19 2014-04-18 4,5-dihydro-pyrazolo [3, 4-c] pyrid-2-ones, preparation method and application thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN201310138026.8 2013-04-19
CN201310138026 2013-04-19
CN201310372920 2013-08-23
CN201310372920.1 2013-08-23
CN201310428690.6A CN104109165A (en) 2013-04-19 2013-09-18 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-one derivatives, and preparation method and application thereof
CN201310428690.6 2013-09-18

Publications (2)

Publication Number Publication Date
WO2014169845A2 WO2014169845A2 (en) 2014-10-23
WO2014169845A3 true WO2014169845A3 (en) 2014-12-11

Family

ID=51706170

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2014/075683 Ceased WO2014169845A2 (en) 2013-04-19 2014-04-18 4,5-dihydro-pyrazolo [3, 4-c] pyrid-2-ones, preparation method and application thereof

Country Status (2)

Country Link
CN (2) CN104109165A (en)
WO (1) WO2014169845A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3064497A1 (en) * 2015-07-20 2016-09-07 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Dimer impurities of apixaban and method to remove them
RS60825B1 (en) 2016-03-17 2020-10-30 Hoffmann La Roche 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar
CN107474030B (en) * 2016-06-08 2021-03-30 首都医科大学 Warfarin-aspirin conjugate, its synthesis, antithrombotic activity and application
CN109232596B (en) * 2018-09-05 2020-03-17 大连九信精细化工有限公司 Synthetic method of dibenzofuran carbazole
CN110143914B (en) * 2019-06-21 2022-03-29 常州恒邦药业有限公司 Preparation method of apixaban intermediate
CA3219657A1 (en) 2021-05-27 2022-12-01 Fanglong Yang Quinolinamine compound, preparation method therefor and application thereof in pharmaceuticals

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1391575A (en) * 1998-12-23 2003-01-15 杜邦药品公司 Nitrogen containing heterobicycles as factor XA inhibitors
US20100048611A1 (en) * 2006-05-31 2010-02-25 Bayer Healthcare Ag Tetrahydropyrrolopyridine, tetrahydropyrazolopyridine, tetrahydro-imidazopyridine and tetrahydrotriazolopyridine derivatives and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1296982B1 (en) * 2000-06-23 2007-09-19 Bristol-Myers Squibb Pharma Company 1-(heteroaryl-phenyl)-condensed pyrazol derivatives as factor xa inhibitors
CN102617567A (en) * 2001-09-21 2012-08-01 百时美施贵宝公司 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
TW200738672A (en) * 2001-12-10 2007-10-16 Bristol Myers Squibb Co Intermediated for the preparation of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
CN101065379B (en) * 2004-09-28 2011-05-11 布里斯托尔-迈尔斯斯奎布公司 Process for preparing 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1391575A (en) * 1998-12-23 2003-01-15 杜邦药品公司 Nitrogen containing heterobicycles as factor XA inhibitors
US20100048611A1 (en) * 2006-05-31 2010-02-25 Bayer Healthcare Ag Tetrahydropyrrolopyridine, tetrahydropyrazolopyridine, tetrahydro-imidazopyridine and tetrahydrotriazolopyridine derivatives and use thereof

Also Published As

Publication number Publication date
WO2014169845A2 (en) 2014-10-23
CN105026392B (en) 2017-05-10
CN105026392A (en) 2015-11-04
CN104109165A (en) 2014-10-22

Similar Documents

Publication Publication Date Title
MY191628A (en) Novel triazolo[4,5-d]pyrimidine derivatives
DK3077397T3 (en) 2-AMINO-6-FLUOR-N- [5-FLUOR-PYRIDIN-3-YL] PYRAZOLO [1,5-A] PYRIMIDIN-3-CARBOXAMIDE COMPOUND USED AS AN AT-KINASE INHIBITOR, DIFFERENTLY DIFFERENTLY DERIVATIVES THEREOF
EP3030266A4 (en) Topical compositions and methods of using the same
WO2014083438A3 (en) Nitric oxide increasing nutritional supplements and methods
EP3064416A4 (en) Vehicle, and method of manufacturing same
EP2968311A4 (en) Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
EP3060041A4 (en) Prostacyclin compounds, compositions and methods of use thereof
WO2014194034A3 (en) Novel metalloproteases
EP2829368A3 (en) Robot and manufacturing method of the same
WO2014086982A3 (en) Stable metal compounds, their compositions and methods of their use
EP2829369A3 (en) Robot and manufacturing method of the same
CA2905610C (en) Hyaluronic acid derivatives
PH12016500643A1 (en) New octahydro - cyclobuta [1,2-c;3,4-c`] dipyrrol -2- yl
WO2012116010A3 (en) Antibiotic tolerance inhibitors
HK1208677A1 (en) Antiviral compound with imidazole-biphenyl-imidazole core
WO2014169845A3 (en) 4,5-dihydro-pyrazolo [3, 4-c] pyrid-2-ones, preparation method and application thereof
MX2015011534A (en) Novel pyrazol derivatives.
PH12015502118A1 (en) Pyridin-4-yl derivatives
NZ716154A (en) Tricyclic benzoxaborole compound, preparation method therefor, and use thereof
WO2016009401A3 (en) Preparation of tedizolid phosphate
EP3053475A4 (en) Manufacturing device and manufacturing method for fastener stringer, as well as fastener stringer
HK1221645A1 (en) Benzoquinolone inhibitors of vmat2
EP3003078A4 (en) Garment part, garment incorporating such garment part and method of manufacturing same
EP3005443B8 (en) Battery assembly and method of manufacturing the same
HK1212978A1 (en) Novel derivatives of sinapinic acid

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480003262.1

Country of ref document: CN

122 Ep: pct application non-entry in european phase

Ref document number: 14786038

Country of ref document: EP

Kind code of ref document: A2